- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| NASCACELL TECHNOLOGIES Aktie jetzt für 0€ handeln |
0 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| LONGEVITY HEALTH | 5,800 | 0,00 % | Pre-market Movers: Longevity Health, SMX (Security Matters), Brazil Potash, Cyclacel Pharmaceuticals, Presidio Property Trust | CANBERA (dpa-AFX) - The following are some of the stocks making big moves in Tuesday's pre-market trading (as of 07.15 A.M. ET).In the Green Longevity Health Holdings, Inc. (XAGE) is up over... ► Artikel lesen | |
| NUVALENT | 82,99 | 0,00 % | Nuvalent, Inc.: Nuvalent Announces Positive Pivotal Data from ARROS-1 Clinical Trial of Zidesamtinib for TKI Pre-treated Patients with Advanced ROS1-positive NSCLC | Aligned with FDA on NDA submission strategy for TKI pre-treated patients with advanced ROS1-positive NSCLC and participation in Real-Time Oncology Review; the... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 5,220 | 0,00 % | Recursion Pharmaceuticals (RXRX) Rallies 8.7% on Hypophosphatasia | ||
| PROKIDNEY | 3,395 | 0,00 % | ProKidney Announces Alignment with the FDA on the Accelerated Approval Pathway for Rilparencel | FDA confirmed that eGFR slope is an acceptable surrogate endpoint for accelerated approval of rilparencel in patients with CKD and type 2 diabetesFDA also confirmed that the ongoing Phase 3 PROACT... ► Artikel lesen | |
| QIAGEN | 41,005 | -0,19 % | Dividendenbekanntmachungen (10.07.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ACCENTURE PLC IE00B4BNMY34 1,48 USD 1,2626 EUR AT&T INC US00206R1023 0,2775 USD 0,2367 EUR AZZ INC US0024741045 0,2 USD 0,1706... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 31,720 | 0,00 % | Avidity Biosciences, Inc.: Avidity Biosciences Announces Positive Topline Phase 1/2 FORTITUDE Data Demonstrating Consistent Improvement Across Multiple Functional Measures Compared to Placebo in Del-Brax Treated FSHD Participants | -- Unprecedented data from FORTITUDE dose escalation cohorts for del-brax treated participants, compared to placebo, demonstrate improvement in function, strength and PROs as well as rapid... ► Artikel lesen | |
| EVOTEC | 7,334 | +0,44 % | Aktienmarkt: Evotec-Aktie tritt auf der Stelle (7,232 €) | Im deutschen Wertpapierhandel ist das Wertpapier von Evotec aktuell unauffällig. Der jüngste Kurs betrug 7,23 Euro. Wenig getan hat sich heute bislang beim Kurs von Evotec. Mit einem Preis von 7,23... ► Artikel lesen | |
| COGENT BIOSCIENCES | 11,500 | 0,00 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Closing of Upsized Public Offering of Shares of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares | ||
| BEAM THERAPEUTICS | 19,580 | 0,00 % | Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 Supporting Differentiated Profile in Sickle Cell Disease (SCD) at European Hematology Association (EHA) 2025 Congress | Updated Data from 17 Patients Consistent with Previously Presented Data; All Patients Treated with BEAM-101 Achieved Hemoglobin F (HbF) Induction of >60%, Hemoglobin S (HbS) Reduction to Patients... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 24,370 | 0,00 % | Summit Therapeutics vor Mega-Deal: Aktie +15% | Papiere von Summit Therapeutics legen heute in der Spitze um +15% zu. Vorausgegangen ist ein Bloomberg-Bericht um einen bevorstehenden Mega-Deals mit dem Pharmakonzern AstraZeneca. Laut Bloomberg News... ► Artikel lesen | |
| ADMA BIOLOGICS | 17,980 | 0,00 % | ADMA Biologics, Inc.: ADMA Biologics Announces First Quarter 2025 Financial Results and Provides Business Update | 1Q 2025 Total Revenue of $114.8 Million (Adjusted Total Revenue(1) of $118.6 Million), a 40% YoY Increase 1Q 2025 GAAP Net Income of $26.9 Million, a 51% YoY Increase 1Q 2025 Adjusted EBITDA(2) of... ► Artikel lesen | |
| BICARA THERAPEUTICS | 10,230 | 0,00 % | Bicara Therapeutics Inc.: Bicara Therapeutics Demonstrates Deep and Durable Responses with Ficerafusp Alfa Plus Pembrolizumab in 1L HPV-Negative R/M HNSCC at ASCO 2025 | Median DOR of 21.7 months with 80% of responders achieving a deep response (=80% tumor shrinkage) Depth and durability translating to prolonged OS with median OS of 21.3 months and 2-year OS of 46%... ► Artikel lesen | |
| CARGO THERAPEUTICS | 4,605 | 0,00 % | Concentra throws lifeline to troubled CARGO Therapeutics | ||
| IMMUNOVANT | 17,490 | 0,00 % | Goldman Sachs nimmt Berichterstattung über Immunovant mit "Neutral"-Rating wieder auf | ||
| PRAXIS PRECISION MEDICINES | 51,93 | 0,00 % | Piper Sandler reiterates Overweight rating on Praxis Precision Medicines stock |
Das Unternehmen NASCACELL TECHNOLOGIES AG kann der Branche Biotechnologie zugeordnet werden.
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NASCACELL TECHNOLOGIES AG finden Sie auf Wallstreet Online.